Cresilon Launches TRAUMAGEL Nationwide in the U.S. 

Cresilon Inc., a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the U.S. commercial launch of TRAUMAGEL, a plant-based hemostatic gel that controls bleeding in seconds when applied to a wound at the point of care.

TRAUMAGEL has received U.S. FDA 510(k) clearance for temporary external use for controlling moderate to severe bleeding and is now available for widespread use by EMTs, paramedics, first responders, emergency departments, and trauma healthcare providers.

Joe Landolina, CEO and co-founder of Cresilon and inventor of the technology commented, “Building on the FDA clearance and success of our strategic rollout, we are launching TRAUMAGEL nationwide and continuing to move forward in our mission to save lives. Not only is TRAUMAGEL a game-changing hemostatic device that can transform the standard of care, but also a life-saving tool that can get patients with traumatic wounds from point A to point B before they bleed to death.”

TRAUMAGEL has already been initially released with regional EMS agencies, fire departments, academic medical centers, and Level I trauma centers in select markets, including Boston, New Orleans, Denver, and Columbus, Ohio. 

“I’ve seen firsthand the unmatched performance of TRAUMAGEL. It’s reliable, easy to use, and stops bleeding extremely fast, even in challenging cases like a ground-level fall patient with a head wound on blood thinners—TRAUMAGEL worked flawlessly and immediately. We’re excited to continue and expand our relationship with Cresilon, bringing this life-saving innovation to even more patients.” said Frank Tranfaglia, Trauma Program Manager at a large Level 1 trauma center in Denver.

The hemostatic gel has been used in the field and applied to a wide variety of moderate to severe bleeds, such as extremity injuries, head lacerations, and penetrating wounds. The results of initial use cases have been positive and will be reported in future case studies.

TRAUMAGEL is the first gel in a syringe for traumatic hemorrhage and is the only flowable hemostatic cleared for temporary external use to control moderate to severe bleeding. 

The company’s proprietary technology is used and blends refined plant polymers to create a durable mechanical barrier when applied to wounds. It is supplied in a 30 mL sterile prefilled syringe, requires no preparation, is easy to apply and remove, rapidly stops bleeding, and is designed to quickly control external moderate to severe bleeding in a variety of wound types and geometries.